Discussion of case reports.
Maertens
Johan
J
Department of Haematology, University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium. johan.maertens@uz.kuleuven.ac.be
D000935:Antifungal Agents / Q000627:therapeutic use*; D001230:Aspergillus / Q000302:isolation & purification*; D002175:Candida / Q000302:isolation & purification*; D002177:Candidiasis / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D018890:Chemoprevention / Q000379:methods; D016638:Critical Illness; D003428:Cross Infection / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D016469:Fungemia / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D016867:Immunocompromised Host; D011183:Postoperative Complications / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D055732:Pulmonary Aspergillosis / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology; D012307:Risk Factors
D000935:Antifungal Agents